Systemic Lupus Erythematosus – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
For the abstract please provide an overview paragraph here and then fill in the bulleted sections below. Feel free to modify the bulleted section. Leverage content from a brochure if you have one.
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. SLE symptoms range from general malaise to serious CNS and renal manifestations. Hydroxychloroquine, corticosteroids, and conventional immunosuppressants are the mainstay treatments for SLE. Unfortunately, many patients with SLE fail to respond to these therapies and/or experience significant adverse events. Clinicians may then prescribe other available agents, such as the biologics Benlysta (GlaxoSmithKline), Saphnelo (AstraZeneca), and Rituxan (Roche; off-label) or the novel calcineurin inhibitor Lupkynis (Aurinia). This content gives manufacturers of current treatments and developers of novel SLE agents insight into the use of SLE drugs and market trends in the SLE space.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed SLE patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed SLE patients?
- How have Benlysta, Saphnelo, and Lupkynis been integrated into the treatment algorithm, and what is their source of business?
- What percentage of SLE patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of SLE patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States.
Key companies: GlaxoSmithKline, AstraZeneca, Aurinia.
Key drugs:
Benlysta, Rituxan, Saphnelo, Lupkynis, mycophenolate mofetil, azathioprine, cyclosporine, cyclophosphamide, hydroxychloroquine, leflunomide, methotrexate, tacrolimus, mycophenolate sodium, Orencia.
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
Table of contents
- Systemic Lupus Erythematosus - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
- Treatment algorithms CDA Systemic lupus erythematosus US April 2023
- Treatment algorithms CDA Systemic lupus erythematosus 2023 Dashboard
Girdhari Roy, Ph.D., Associate Healthcare Research & Data Analyst, Immune and Inflammation. Prior to joining Clarivate, Dr. Roy was a product selection and ideation scientist at Dr. Reddy’s Laboratory. He also worked as a drug metabolism and pharmacokinetics scientist at ADTL Hyderabad. He holds bachelor’s and master’s degrees in pharmacy and a doctorate in pharmaceutical sciences from BITS Pilani, Hyderabad Campus, India.